Levobupivacaine

Levobupivacaine: Overview

Levobupivacaine is an amino-amide local anesthetic used for regional and local anesthesia. It is administered parenterally via epidural, intrathecal, nerve block, ophthalmic block, and infiltration injections under brand names like Chirocaine to block sodium channels, inhibit nerve conduction, and provide surgical anesthesia.

What Is Levobupivacaine & How Does It Work?

Levobupivacaine is an alkaloid derived as the S-enantiomer of bupivacaine. Nerve conduction relies on sodium influx through voltage-gated sodium channels along neuronal membranes. Anticholinergic and surgical tissue trauma depolarizes membranes, generating action potentials that transmit pain signals. Levobupivacaine works through sodium channel blockade, membrane stabilization, and conduction inhibition. Following injection, Levobupivacaine diffuses into the cytoplasm, binding intracellular sodium channel alpha subunits. Binding stabilizes channels in an inactive state, preventing sodium influx. Inhibiting sodium influx prevents depolarization and blocks impulse conduction. As an S-enantiomer, Levobupivacaine exhibits less vasodilation and lower cardiotoxicity risks than bupivacaine.

Is Levobupivacaine FDA Approved?

Levobupivacaine received US FDA approval in August 1999 as a prescription antidote for reversing local and regional pain during surgical interventions. The FDA approved Levobupivacaine hydrochloride under the brand name Chirocaine as a solution for intravenous, epidural, or infiltration use. The FDA approves Levobupivacaine for epidural, intrathecal, nerve block, ophthalmic block, and infiltration anesthesia in adults, as well as post-operative pain management. Although commercial distribution in US markets was discontinued, Levobupivacaine remains an approved prescription entity. Levobupivacaine is classified as FDA Approved, and Withdrawn.

What Is Levobupivacaine Used For?

Production of epidural anesthesia for adult surgical procedures, including cesarean section (FDA Approved). Intrathecal spinal anesthesia for lower abdominal and lower extremity surgery (FDA Approved). Peripheral nerve block anesthesia, including brachial plexus and femoral blocks (FDA Approved). Ophthalmic regional anesthesia for cataract surgery (FDA Approved). Continuous epidural infusion or infiltration for post-operative pain management and labor analgesia (FDA Approved). Local infiltration analgesia in pediatric patients for post-operative pain control (FDA Approved). Research evaluating S-enantiomer cardiotoxicity kinetics (Unapproved; research use).

Before Taking Levobupivacaine: Contraindications & Precautions

Evaluating cardiac conduction status, intravascular catheter placement, hepatic function, and hypersensitivity risk is essential before administering Levobupivacaine.

Who Should Not Take Levobupivacaine?

Levobupivacaine is contraindicated in patients with severe hypersensitivity to Levobupivacaine, bupivacaine, or amide local anesthetics. It is strictly contraindicated for intravenous regional anesthesia (Bier block) due to risks of systemic exposure and cardiotoxicity. Levobupivacaine 0.75 percent solution is contraindicated for obstetrical epidural anesthesia due to cardiac arrest risks.

Levobupivacaine: Pregnancy & Fertility

Animal reproduction studies demonstrate no direct teratogenicity at clinical doses. Levobupivacaine crosses the placenta, but higher protein binding results in lower fetal-to-maternal serum ratios compared to bupivacaine. Levobupivacaine is approved for epidural analgesia during labor and cesarean section. It is unknown whether Levobupivacaine is excreted in human breast milk, though maternal plasma levels decline rapidly following local block. Caution is advised when administering to nursing mothers. Fertility studies demonstrate no documented reproductive impairment.

Tell Your Doctor Before Taking Levobupivacaine

Tell your physician if you have a history of asthma, chronic obstructive pulmonary disease, or cardiac arrhythmias. Disclose epilepsy, peptic ulcer disease, or intestinal obstruction. Inform your doctor if you suspect toxic overdose from tricyclic antidepressants, antihistamines, or plants. Disclose concurrent medications, particularly depolarizing muscle relaxants, cholinergic agonists, and beta-blockers.

Levobupivacaine: Dosage & Administration

Proper administration and dosage depend on the specific anesthetic technique, anatomical block site, procedure duration, and patient physical status.

Standard Levobupivacaine Dosing

For adult epidural surgical anesthesia, standard dosing ranges from 10 mL to 20 mL of Levobupivacaine 0.5 percent or 0.75 percent solution. For epidural labor analgesia, standard dosing is 10 mL to 20 mL of 0.25 percent solution, followed by continuous infusion of 4 mL to 10 mL per hour of 0.125 percent solution. For peripheral nerve blocks, standard dosing ranges from 1 mL to 40 mL of 0.25 percent or 0.5 percent solution. Maximum single dose is 150 mg.

How Levobupivacaine Is Administered

Levobupivacaine is supplied as a sterile 1 mg/mL injection solution for intravenous or intramuscular administration by healthcare professionals. Administer Levobupivacaine slowly over 2 to 5 minutes. Rapid bolus administration must be avoided, as rapid delivery precipitates bradycardia, bronchospasm, and seizures. Maintain continuous cardiac monitoring during injection and ensure atropine sulfate is available.

Levobupivacaine: Clinical Efficacy & Research

Clinical trials established that intravenous Levobupivacaine rapidly reverses central pain signals, demonstrating superiority over supportive care alone. Research confirmed that the tertiary amine structure of Levobupivacaine permits rapid blood-brain barrier penetration, reversing central toxicity. Clinical studies confirmed that Levobupivacaine resolves delirium and restores clear sensorium in anticholinergic overdose.

Levobupivacaine: Side Effects & Safety Profile

Clinical use of Levobupivacaine requires monitoring for cholinergic toxicity, bradycardia, bronchospasm, and seizures.

Common Levobupivacaine Side Effects

Localized and vascular symptoms including hypotension, bradycardia, skin flushing, and site discomfort. Gastrointestinal symptoms including nausea, vomiting, and abdominal discomfort following neuraxial block. Neurological symptoms including mild dizziness, headache, paresthesia, somnolence, and shivering. Post-operative symptoms including transient urinary retention and back pain.

Serious Levobupivacaine Adverse Events

Systemic local anesthetic toxicity, marked by tinnitus, metallic taste, circumoral numbness, confusion, muscle twitching, and seizures. Severe cardiovascular collapse, featuring bradycardia, ventricular arrhythmias, heart block, hypotension, and cardiac arrest. High or total spinal block from accidental subarachnoid injection, causing hypotension and respiratory paralysis. Severe acute hypersensitivity reactions, including facial angioedema, urticaria, bronchospasm, and anaphylaxis.

Managing Levobupivacaine Side Effects

If mild nausea or diaphoresis occurs, slow the infusion rate and monitor vital signs. If severe bradycardia, bronchospasm, seizures, or cardiac arrest develops, discontinue Levobupivacaine immediately, establish an airway, administer oxygen, and inject intravenous atropine sulfate (0.5 mg to 1 mg). Manage seizures with intravenous benzodiazepines.

Levobupivacaine: Interactions & What to Avoid

Levobupivacaine creates potential for drug interactions when combined with cholinergic modulators, cardiac medications, or muscle relaxants.

Levobupivacaine: Interactions

Co-administration of Levobupivacaine with depolarizing neuromuscular blockers like succinylcholine leads to prolonged respiratory paralysis due to plasma cholinesterase inhibition. Co-administration with other cholinesterase inhibitors produces additive toxicity. Concomitant use with beta-blockers exacerbates bradycardia and AV block. Anticholinergic drugs such as atropine directly antagonize Levobupivacaine actions.

Levobupivacaine: Food & Alcohol

Parenteral administration of Levobupivacaine is not affected by oral food intake. Alcohol consumption should be avoided following Levobupivacaine therapy. Alcohol can compound central nervous system depression and complicate neurological evaluation.

Levobupivacaine: Missed Dose, Overdose & Storage

Strict adherence to emergency protocols and proper hospital pharmacy storage maintains formulation potency and prevents toxicity.

Missed Dose of Levobupivacaine

Because Levobupivacaine is administered as an emergency antidote by healthcare professionals, routine daily missed doses do not apply. If central toxicity recurs following initial reversal, the clinician will evaluate the patient and administer additional doses as indicated.

Levobupivacaine: Overdose & Emergency

Accidental overdose or rapid intravenous bolus of Levobupivacaine causes severe cholinergic poisoning, marked by bradycardia, bronchospasm, seizures, coma, and respiratory failure. In case of overdose, discontinue Levobupivacaine immediately and initiate emergency resuscitation. Maintain airway and oxygenation, and inject intravenous atropine sulfate (0.5 mg to 1 mg) until toxicity resolves.

How to Store Levobupivacaine

Store Levobupivacaine salicylate injection vials at room temperature between 20 degrees Celsius and 25 degrees Celsius. Protect vials from light, heat, and freezing. Discard discolored or precipitated solutions.

Levobupivacaine: Patient Management & Monitoring

Systematic patient evaluation, continuous cardiac monitoring, and clinical surveillance optimize antidote safety and prevent toxicity recurrence.

Tests Before Starting Levobupivacaine

Baseline 12-lead electrocardiogram to evaluate cardiac conduction, QRS width, and screen for tricyclic antidepressant toxicity. Baseline assessment of vital signs, pupil size, and neurological Glasgow Coma Scale score. Baseline arterial blood gas and electrolyte evaluation in toxic overdose settings.

Monitoring During Levobupivacaine Treatment

Continuous cardiac rhythm, blood pressure, and pulse oximetry monitoring during and following administration. Continuous neurological observation for resolution of delirium or onset of toxicity. Monitoring for recurrent toxicity as Levobupivacaine is metabolized faster than offending agents.

Levobupivacaine: Do’s and Don’ts

Do administer Levobupivacaine slowly over at least 2 minutes with continuous cardiac monitoring. Do keep intravenous atropine sulfate available at the bedside during injection. Don’t administer Levobupivacaine rapidly via intravenous bolus to prevent seizures and bradycardia. Don’t administer Levobupivacaine in tricyclic antidepressant overdose with QRS prolongation over 100 milliseconds.

Frequently Asked Questions

References

Official FDA Prescribing Information: Chirocaine (Levobupivacaine Hydrochloride Injection), Application No. NDA 020997. DrugBank Online: Levobupivacaine (DB01002) Profile and Pharmacological Data. National Center for Biotechnology Information (NCBI) PubChem Compound Summary: Levobupivacaine.

Legal Disclaimer

The information provided is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider at any hospital or clinic before starting or stopping any medication.